Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Pacira BioSciences, Inc.

82P
Current price
15.6 EUR +0.2 EUR (+1.30%)
Last closed 16.45 USD
ISIN US6951271005
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange Frankfurt Exchange
Capitalization 808 030 976 USD
Yield for 12 month -40.61 %
1Y
3Y
5Y
10Y
15Y
82P
21.11.2021 - 28.11.2021

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida. Address: 5401 West Kennedy Boulevard, Tampa, FL, United States, 33609

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

24.5 USD

P/E ratio

Dividend Yield

Current Year

+674 978 000 USD

Last Year

+666 823 000 USD

Current Quarter

+168 573 000 USD

Last Quarter

+178 023 000 USD

Current Year

+433 021 000 USD

Last Year

+467 528 000 USD

Current Quarter

+168 573 000 USD

Last Quarter

+119 439 000 USD

Key Figures 82P

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 178 032 992 USD
Operating Margin TTM 13.02 %
PE Ratio
Return On Assets TTM 4.17 %
PEG Ratio -3.83
Return On Equity TTM -11.48 %
Wall Street Target Price 24.5 USD
Revenue TTM 694 956 992 USD
Book Value 16.24 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 2.8 %
Dividend Yield
Gross Profit TTM 393 231 000 USD
Earnings per share -1.98 USD
Diluted Eps TTM -1.98 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY -24.5 %
Profit Margin -13.06 %

Dividend Analytics 82P

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History 82P

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation 82P

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 4.6533
Enterprise Value Revenue 1.4197
Price Sales TTM 1.1454
Enterprise Value EBITDA 29.5198
Price Book MRQ 1.062

Financials 82P

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 82P

For 52 weeks

11.16 USD 35.95 USD
50 Day MA 15.62 USD
Shares Short Prior Month 6 311 164
200 Day MA 23.44 USD
Short Ratio 6.05
Shares Short 6 140 722
Short Percent 19.39 %